GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

KSP-1007   Click here for help

GtoPdb Ligand ID: 13547

Compound class: Synthetic organic
Comment: KSP-1007 is a bicyclic boronic acid β-lactamase inhibitor (BLI), with broad-spectrum activity against both serine and metallo-β-lactamases, discovered through a collaboration between the Kitasato Institute (Tokyo, Japan) and Sumitomo Pharma (Osaka, Japan) [1]. KSP-1007, in combination with meropenem, is under clinical development for the treatment of infections caused by carbapenem-resistant bacterial infections.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 6
Topological polar surface area 146.71
Molecular weight 386.17
XLogP -1.14
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=C2CCB(O)OC2=C(C(=C1)OC3CN(C3)C(=O)[C@@H](C4=CNC=N4)N)C(=O)O
Isomeric SMILES C1=CC(=C(C2=C1CCB(O)O2)C(=O)O)OC3CN(C3)C(=O)[C@@H](C4=CNC=N4)N
InChI InChI=1S/C17H19BN4O6/c19-14(11-5-20-8-21-11)16(23)22-6-10(7-22)27-12-2-1-9-3-4-18(26)28-15(9)13(12)17(24)25/h1-2,5,8,10,14,26H,3-4,6-7,19H2,(H,20,21)(H,24,25)/t14-/m1/s1
InChI Key CAHUDGVGUAJGGS-CQSZACIVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
KSP-1007 is administered intravenously. In September 2022, KSP-1007 in combination with meropenem, was granted Qualified Infectious Disease Product (QIDP) and Fast Track Designation by the US FDA for the treatment of hospital acquired pneumonia (HAP) including ventilator-associated bacterial pneumonia (VAP), complicated urinary tract infections and complicated intra-abdominal infections. A Phase 1 study (NCT05226923) to assess the safety, tolerability, and pharmacokinetics of KSP-1007, alone and co-administered with meropenem, has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05226923 Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects Phase 1 Interventional Sumitovant Biopharma, Inc.